Fibogest H 250mg Injection contains Hydroxyprogesterone, a synthetic form of the naturally occurring hormone progesterone, at a concentration of 250mg per dose. It is primarily used in the prevention of preterm birth in pregnant women who have a history of spontaneous preterm delivery. By mimicking the effects of natural progesterone, Fibogest H helps maintain uterine quiescence and supports the pregnancy by reducing uterine contractions and inflammation. This injectable formulation allows for intramuscular administration, ensuring effective absorption and sustained release of the hormone. It is typically prescribed by healthcare professionals and administered once weekly, starting from the second trimester until 36 weeks of gestation or delivery, whichever comes first. Besides its role in obstetrics, Hydroxyprogesterone may also be used in certain cases of menstrual disorders or hormone replacement therapy under medical supervision. Patients receiving Fibogest H should be monitored for potential side effects such as injection site reactions, fluid retention, or allergic responses. It is contraindicated in individuals with known hypersensitivity to progesterone or its derivatives, active thrombophlebitis, or liver dysfunction. Proper medical guidance and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize risks associated with this medication.